The RTKs IGF-1R, EGFR, and MET were overexpressed in patient-derived ACC cells, while differentiation of ACC cells and synergistic inhibition of ACC xenograft growth was achieved by the combination of linsitinib (IGF-1R inhibitor, Figure 5), gefitinib (EGFR inhibitor), and crizotinib (MET inhibitor). The gene discussed is MET; the disease is adrenal cortex carcinoma.